New hope for HER2 cancers: first human trial launches
NCT ID NCT05356741
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 23 times
Summary
This study tests a new drug called VIR-5818, alone or with another drug (pembrolizumab), in people with advanced HER2-positive cancers that have spread. The main goals are to check safety and find the right dose. About 645 adults with various HER2-expressing tumors will take part. The study lasts about 52 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC HER2-EXPRESSING CANCERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Investigational site number #100
RECRUITINGMelbourne, Victoria, 3000, Australia
-
Investigational site number #101
RECRUITINGRandwick, 2031, Australia
-
Investigational site number #150
RECRUITINGToulouse, 31059, France
-
Investigational site number #200
RECRUITINGPorto, 4200-072, Portugal
-
Investigational site number #250
RECRUITINGPamplona, 31008, Spain
-
Investigational site number #251
RECRUITINGBarcelona, 08035, Spain
-
Investigational site number #252
RECRUITINGMadrid, 28050, Spain
-
Investigational site number #253
RECRUITINGPozuelo de Alarcón, 28223, Spain
-
Investigational site number #254
RECRUITINGMadrid, 28027, Spain
-
Investigational site number #255
RECRUITINGBarcelona, 08023, Spain
Conditions
Explore the condition pages connected to this study.